Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The objective of the present study was to identify proteins that contribute to pathophysiology and allow prediction of incident type 2 diabetes or incident prediabetes. We quantified 14 candidate proteins using targeted mass spectrometry in plasma samples of the prospective, population-based German KORA F4/FF4 study (6.5-year follow-up). 892 participants aged 42-81 years were selected using a case-cohort design, including 123 persons with incident type 2 diabetes and 255 persons with incident WHO-defined prediabetes. Prospective associations between protein levels and diabetes, prediabetes as well as continuous fasting and 2 h glucose, fasting insulin and insulin resistance were investigated using regression models adjusted for established risk factors. The best predictive panel of proteins on top of a non-invasive risk factor model or on top of HbA1c, age, and sex was selected. Mannan-binding lectin serine peptidase (MASP) levels were positively associated with both incident type 2 diabetes and prediabetes. Adiponectin was inversely associated with incident type 2 diabetes. MASP, adiponectin, apolipoprotein A-IV, apolipoprotein C-II, C-reactive protein, and glycosylphosphatidylinositol specific phospholipase D1 were associated with individual continuous outcomes. The combination of MASP, apolipoprotein E (apoE) and adiponectin improved diabetes prediction on top of both reference models, while prediabetes prediction was improved by MASP plus CRP on top of the HbA1c model. In conclusion, our mass spectrometric approach revealed a novel association of MASP with incident type 2 diabetes and incident prediabetes. In combination, MASP, adiponectin and apoE improved type 2 diabetes prediction beyond non-invasive risk factors or HbA1c, age and sex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Targeted MS methods have been developed, again especially where interferences obfuscate immunoassays128 or where additional biological context is required129.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966 · cited 1×
“Type 2 diabetes causes an enormous burden for the individual as well as for societies of many countries worldwide [1].”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Pencina, M. J., D'Agostino, R. B., & Steyerberg, E. W. (2011) · Statistics in Medicine · doi:10.1002/sim.4085 · Cited by 2,453
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw152 · Cited by 847 · cited 1×
“The main advantage of HbA1c in contrast to glucose is its spontaneous availability, avoiding fasting, which is no longer required in routine clinical practice [18], and avoiding oral glucose tolerance test (OGTT) burden [19].”
BackgroundSelf-citationGall, W. E., Beebe, K., Lawton, K. A., Adam, K.-P., Mitchell, M. W., Nakhle, P. J., Ryals, J. A., Milburn, M. V., Nannipieri, M., Camastra, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010883 · Cited by 698 · cited 1×
“Research on type 2 diabetes risk stratification either aims at diagnosis of insulin resistance or prediabetes [6, 7] or attempts to directly predict the future risk of diabetes [7–10].”
BackgroundLiu, C., Feng, X., Li, Q., Wang, Y., Li, Q., & Hua, M. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.028 · Cited by 470
Schulze, M. B., Hoffmann, K., Boeing, H., Linseisen, J., Rohrmann, S., Möhlig, M., Pfeiffer, A. F. H., Spranger, J., Thamer, C., Häring, H.-U., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2089 · Cited by 372
Thiel, S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.005 · Cited by 253
Novel biomarkers for prediabetes, diabetes, and associated complications
Dorcely, B., Katz, K., Jagannathan, R., Chiang, S. S., Oluwadare, B., Goldberg, I. J., & Bergman, M. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s100074 · Cited by 219
Abbatiello, S. E., Mani, D. R., Keshishian, H., & Carr, S. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.138420 · Cited by 198
Definition, Klassifikation und Diagnostik des Diabetes mellitus
Nauck, M., Petermann, A., Müller-Wieland, D., Kerner, W., Müller, U., Landgraf, R., Freckmann, G., & Heinemann, L. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115953 · Cited by 175
New Metrics for Assessing Diagnostic Potential of Candidate Biomarkers
Pickering, J. W., & Endre, Z. H. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09590911 · Cited by 173
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
Salomaa, V., Havulinna, A., Saarela, O., Zeller, T., Jousilahti, P., Jula, A., Muenzel, T., Aromaa, A., Evans, A., Kuulasmaa, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010100 · Cited by 169
Early metabolic markers identify potential targets for the prevention of type 2 diabetes
Peddinti, G., Cobb, J., Yengo, L., Froguel, P., Kravić, J., Balkau, B., Tuomi, T., Aittokallio, T., & Groop, L. (2017) · Diabetologia · doi:10.1007/s00125-017-4325-0 · Cited by 138
Screening for type 2 diabetes: a short report for the National Screening Committee
Waugh, N., Shyangdan, D., Taylor-Phillips, S., Suri, G., & Hall, B. (2013) · Health Technology Assessment · doi:10.3310/hta17350 · Cited by 130 · cited 1×
“The main advantage of HbA1c in contrast to glucose is its spontaneous availability, avoiding fasting, which is no longer required in routine clinical practice [18], and avoiding oral glucose tolerance test (OGTT) burden [19].”
BackgroundProtein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts
Nowak, C., Sundström, J., Gustafsson, S., Giedraitis, V., Lind, L., Ingelsson, E., & Fall, T. (2016) · Diabetes · doi:10.2337/db15-0881 · Cited by 120 · cited 1×
“Research on type 2 diabetes risk stratification either aims at diagnosis of insulin resistance or prediabetes [6, 7] or attempts to directly predict the future risk of diabetes [7–10].”
BackgroundAnderson, J. P., Parikh, J. R., Shenfeld, D. K., Ivanov, V., Marks, C., Church, B. W., Laramie, J. M., Mardekian, J., Piper, B. A., Willke, R. J., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815620200 · Cited by 110
Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation
Dobó, J., Schroeder, V., Jenny, L., Cervenak, L., Závodszky, P., & Gál, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.013 · Cited by 107
Bongaerts, B. W. C., Rathmann, W., Heier, M., Kowall, B., Herder, C., Stöckl, D., Meisinger, C., & Ziegler, D. (2013) · Diabetes Care · doi:10.2337/dc12-0744 · Cited by 106
Self-citationMASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study
von Toerne, C., Huth, C., Gala, T. D. L. H., Kronenberg, F., Herder, C., Köenig, W., Meisinger, C., Rathmann, W., Waldenberger, M., Roden, M., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4024-2 · Cited by 96 · cited 13×
“The plasma samples of 271 persons of the subcohort had already been measured previously (lot 1) [23].”
BackgroundMethodInfluentialSelf-citationThiel, S., Jensen, L., Degn, S. E., Nielsen, H. J., Gál, P., Dobó, J., & Jensenius, J. C. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04584.x · Cited by 94
Kollerits, B., Lamina, C., Huth, C., Marques-Vidal, P. M., Kiechl, S. J., Seppälä, I., Cooper, J. A., Hunt, S. C., Meisinger, C., Herder, C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0201 · Cited by 92
Self-citationLam, C. S. P., Chen, M.-H., Lacey, S. M., Yang, Q., Sullivan, L. M., Xanthakis, V., Safa, R., Smith, H. M., Peng, X., Sawyer, D. B., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.203943 · Cited by 89
Huth, C., Beuerle, S., Zierer, A., Heier, M., Herder, C., Kaiser, T., Köenig, W., Kronenberg, F., Oexle, K., Rathmann, W., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0631 · Cited by 84
Self-citationThe potential of novel biomarkers to improve risk prediction of type 2 diabetes
Herder, C., Kowall, B., Tabák, Á. G., & Rathmann, W. (2013) · Diabetologia · doi:10.1007/s00125-013-3061-3 · Cited by 81
Self-citationRathmann, W., Kowall, B., Heier, M., Herder, C., Holle, R., Thorand, B., Strassburger, K., Peters, A., Wichmann, H. ‐., Giani, G., et al. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03065.x · Cited by 74
Self-citationAbbasi, A., Sahlqvist, A., Lotta, L. A., Brosnan, J. M., Vollenweider, P., Giabbanelli, P. J., Nunez, D. J., Waterworth, D. M., Scott, R. A., Langenberg, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163721 · Cited by 68
Cortesio, C. L., & Jiang, W. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.02.006 · Cited by 66
Laxy, M., Knoll, G., Schunk, M. V., Meisinger, C., Huth, C., & Holle, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164704 · Cited by 64 · cited 1×
“The study design has been described previously in detail [20].”
MethodSelf-citationPaprott, R., Mühlenbruch, K., Mensink, G., Thiele, S., Schulze, M. B., Scheidt‐Nave, C., & Heidemann, C. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000280 · Cited by 64
Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks
Onat, A., Hergenç, G., Ayhan, E., Uğur, M., Kaya, H., Tuncer, M., & Can, G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02814.x · Cited by 55
Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study
Brahimaj, A., Ligthart, S., Ikram, M. A., Hofman, A., Franco, O. H., Sijbrands, E. J. G., Kavousi, M., & Dehghan, A. (2016) · Diabetes Care · doi:10.2337/dc16-1295 · Cited by 55
Echouffo-Tcheugui, J. B., Dieffenbach, S. D., & Kengne, A. P. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.023 · Cited by 38
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Apolipoprotein CIII is a new player in diabetes
Juntti‐Berggren, L., & Berggren, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000372 · Cited by 30 · cited 1×
“Apart from the pathogenic role of higher triglyceride levels associated with higher apolipoprotein levels [39], and their possible role in inflammatory pathways [38], it was shown in animal and cell studies that apoC-III may promote the development of diabetes directly, by interfering with both function and survival o…”
BackgroundHerder, C., Kannenberg, J. M., Niersmann, C., Huth, C., Carstensen‐Kirberg, M., Wittenbecher, C., Schulze, M. B., Blüher, M., Rathmann, W., Peters, A., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0100 · Cited by 28
Self-citationKing, B. C., & Blom, A. M. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.12.009 · Cited by 25
Krogh, S., Holt, C. B., Steffensen, R., Funck, K. L., Høyem, P., Laugesen, E., Poulsen, P. L., Thiel, S., & Hansen, T. K. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12963 · Cited by 22
Definition, Klassifikation und Diagnostik des Diabetes mellitus
Nauck, M. A., Petersmann, A., Müller‐Wieland, D., Schleicher, E. D., Müller, U., Landgraf, R., Freckmann, G., & Heinemann, L. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0598-0527 · Cited by 17
(2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-114607 · Cited by 7
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Research works printed but not linked: 1
- WHO. Global report on diabetes. Geneva, Switzerland: WHO Press; 2006.
Cited by
Objectives, design and main findings until 2020 from the Rotterdam Study
Ikram, M. A., Brusselle, G., Ghanbari, M., Goedegebure, A., Ikram, M. K., Kavousi, M., Kieboom, B. C. T., Klaver, C. C. W., de Knegt, R. J., Luik, A. I., et al. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00640-5 · Cited by 452
Petrera, A., von Toerne, C., Behler, J., Huth, C., Thorand, B., Hilgendorff, A., & Hauck, S. M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00641 · Cited by 216
Self-citationA high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Blood protein assessment of leading incident diseases and mortality in the UK Biobank
Gadd, D. A., Hillary, R. F., Kuncheva, Z., Mangelis, T., Cheng, Y., Dissanayake, M., Admanit, R., Gagnon, J., Lin, T., Ferber, K. L., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00655-7 · Cited by 142
Advances in multi-omics study of biomarkers of glycolipid metabolism disorder
Fang, X., Miao, R., Wei, J., Wu, H., & Tian, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.10.030 · Cited by 125
“identified proteins related to the prediction and early diagnosis of T2DM [100].”
Background
Metadata
- Authors
- Huth, C., von Toerne, C., Schederecker, F., de las Heras Gala, T., Herder, C., Kronenberg, F., Meisinger, C., Rathmann, W., Koenig, W., Waldenberger, M., Roden, M., Peters, A., Hauck, S. M., & Thorand, B.
- Affiliations
- Helmholtz Munich (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Innsbruck Medical University (AT)
- Corresponding author
- Huth, Cornelia
- ORCID
- Venue
- European Journal of Epidemiology
- Published
- 2018-12-31
- Volume
- 34
- Issue
- 4
- Pages
- 409-422
- ISSN
- 0393-2990 (ISSN-L)
- 1573-7284
- PMC
- PMC6451724
- OpenAlex
- W2907303285
- Cited by
- 56
- References
- 44
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 14 · 2020: 12 · 2019: 1 · 2018: 1
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Journal of Epidemiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Site cant be reached (submittedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Bundesministerium für Bildung und Forschung
- Ministerium für Wissenschaft und Forschung Nordrhein-Westfalen
- Bundesministerium für Gesundheit
- Bundesland Bayern
- Munich Center of Health Sciences
- Deutsche Forschungsgemeinschaft (DFG, RA 459/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- type 2 diabetes, prediabetes, plasma protein biomarkers, adiponectin, apolipoprotein E, C-reactive protein, apolipoprotein A-IV, apolipoprotein C-II, diabetes risk prediction, insulin resistance, HbA1c
- MeSH terms
- Adult, Aged, Aged, 80 and over, Apolipoproteins E, Diabetes Mellitus, Type 2, Female, Germany, Humans, Male, Middle Aged, Prediabetic State, Prospective Studies, Risk Factors, Biomarkers, Proteomics, Mannose-Binding Protein-Associated Serine Proteases, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.